William Blair Cuts Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Analysts at William Blair reduced their FY2025 earnings estimates for shares of Krystal Biotech in a research note issued to investors on Monday, July 14th. William Blair analyst S. Corwin now forecasts that the company will post earnings per share of $5.43 for the year, down from their previous estimate of $5.89. The consensus estimate for Krystal Biotech's current full-year earnings is $6.14 per share.

Several other equities research analysts have also issued reports on KRYS. Chardan Capital reiterated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. Guggenheim cut their target price on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a research note on Wednesday, July 9th. Finally, HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a report on Tuesday, June 24th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $213.75.

Krystal Biotech Price Performance

NASDAQ KRYS traded down $2.68 during trading on Tuesday, reaching $147.73. The company's stock had a trading volume of 322,915 shares, compared to its average volume of 287,552. The firm has a fifty day moving average of $135.59 and a 200 day moving average of $156.16. Krystal Biotech has a one year low of $122.80 and a one year high of $219.34. The stock has a market capitalization of $4.27 billion, a PE ratio of 33.50 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The firm had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KRYS. Crossmark Global Holdings Inc. lifted its stake in shares of Krystal Biotech by 2.7% in the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock valued at $427,000 after purchasing an additional 63 shares during the period. Summit Investment Advisors Inc. raised its holdings in Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after buying an additional 82 shares during the last quarter. Xponance Inc. grew its holdings in shares of Krystal Biotech by 4.9% during the first quarter. Xponance Inc. now owns 1,873 shares of the company's stock valued at $338,000 after buying an additional 88 shares during the last quarter. Sound View Wealth Advisors Group LLC grew its holdings in shares of Krystal Biotech by 6.7% during the first quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock valued at $273,000 after buying an additional 95 shares during the last quarter. Finally, New York State Teachers Retirement System increased its position in shares of Krystal Biotech by 0.6% during the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock valued at $2,881,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 86.29% of the company's stock.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $150.27, for a total transaction of $1,040,920.29. Following the completion of the sale, the insider owned 1,525,929 shares of the company's stock, valued at $229,301,350.83. This represents a 0.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 13,927 shares of company stock valued at $2,092,852 over the last quarter. 13.70% of the stock is owned by insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).